BioCentury | Oct 24, 2016
Strategy

Lilly’s history lesson

...the compound could be first in class in two of the three indications. Amgen Inc.’s fulranumab...
BioCentury | Jul 11, 2016
Company News

Amgen, Takeda deal

...Takeda said it returned its Japanese rights to fulranumab ( AMG 403 ) and trebananib ( AMG...
...April, Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) said it discontinued Phase III testing of fulranumab...
BioCentury | Jun 25, 2016
Company News

Takeda ends Japan deal for two Amgen candidates

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it returned its Japanese rights to fulranumab ( AMG 403...
...Inc. (NASDAQ:AMGN). In April, Johnson & Johnson (NYSE:JNJ) said it discontinued Phase III development of fulranumab...
BioCentury | May 3, 2016
Top Story

Regeneron's anti-NGF mAb meets Phase II/III endpoint

...Last month, Johnson & Johnson (NYSE:JNJ) returned to Amgen Inc. (NYSE:AMGN) rights to fulranumab ( AMG 403...
BioCentury | Apr 11, 2016
Company News

Amgen, J&J deal

...& Johnson said it will discontinue its Phase III development program for osteoarthritis pain candidate fulranumab...
...outside of Japan from Amgen under a 2008 deal, will return all rights to Amgen. Fulranumab...
BioCentury | Apr 2, 2016
Company News

Janssen returns Phase III anti-NGF mAb to Amgen

...& Johnson (NYSE:JNJ) said it will discontinue its Phase III development program for fulranumab ( AMG 403...
...studies. Janssen paid $50 million up front in 2008 for exclusive, worldwide ex-Japan rights to fulranumab...
BioCentury | Mar 19, 2012
Clinical News

Fulranumab regulatory update

...as interstitial cystitis or chronic pancreatitis. Tanezumab was in Phase III testing for OA pain, fulranumab...
...products with demonstrated analgesic efficacy, such as interstitial cystitis or chronic pancreatitis. Product: Fulranumab ( AMG 403...
...placed clinical holds on 3 mAbs against NGF due to safety concerns for the class: fulranumab...
BioCentury | Mar 13, 2012
Clinical News

Panel backs anti-NGF development for OA

...holds on three mAbs against NGF due to safety concerns for the class: fulranumab ( AMG 403...
...and tanezumab from Pfizer Inc. (NYSE:PFE). Tanezumab was in Phase III testing for OA pain, fulranumab...
BioCentury | Mar 9, 2012
Company News

FDA panel to consider role of anti-NGF compounds

...holds on three anti-NGF pain candidates due to safety concerns for the class: fulranumab ( AMG 403...
...from Pfizer. Last May, FDA lifted a clinical hold on a Phase II trial of fulranumab...
BioCentury | Sep 10, 2011
Politics & Policy

FDA postpones anti-NGF meeting

...at least three anti-NGF pain candidates due to safety concerns for the class: fulranumab ( AMG 403...
...Inc. (NYSE:PFE). In May, FDA lifted a clinical hold on a Phase II trial of fulranumab...
Items per page:
1 - 10 of 22